nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—Sleep disturbance—Varenicline—nicotine dependence	0.0375	0.0517	CcSEcCtD
Moclobemide—Delusion—Varenicline—nicotine dependence	0.0297	0.041	CcSEcCtD
Moclobemide—Gingivitis—Varenicline—nicotine dependence	0.0268	0.0369	CcSEcCtD
Moclobemide—Aggression—Varenicline—nicotine dependence	0.0239	0.033	CcSEcCtD
Moclobemide—Dysarthria—Varenicline—nicotine dependence	0.0222	0.0307	CcSEcCtD
Moclobemide—Nightmare—Varenicline—nicotine dependence	0.0203	0.028	CcSEcCtD
Moclobemide—Urine output increased—Varenicline—nicotine dependence	0.019	0.0262	CcSEcCtD
Moclobemide—Sleep disorder—Varenicline—nicotine dependence	0.0176	0.0243	CcSEcCtD
Moclobemide—Polyuria—Varenicline—nicotine dependence	0.0174	0.024	CcSEcCtD
Moclobemide—Disorientation—Varenicline—nicotine dependence	0.017	0.0235	CcSEcCtD
Moclobemide—CYP2C19—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0169	0.0672	CbGpPWpGaD
Moclobemide—Hot flush—Varenicline—nicotine dependence	0.0163	0.0225	CcSEcCtD
Moclobemide—Minaprine—DRD2—nicotine dependence	0.0162	0.679	CrCbGaD
Moclobemide—Menopausal symptoms—Varenicline—nicotine dependence	0.0162	0.0223	CcSEcCtD
Moclobemide—Visual disturbance—Varenicline—nicotine dependence	0.0161	0.0222	CcSEcCtD
Moclobemide—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0156	0.0618	CbGpPWpGaD
Moclobemide—CYP2C9—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0154	0.0613	CbGpPWpGaD
Moclobemide—Osteoarthritis—Varenicline—nicotine dependence	0.0152	0.021	CcSEcCtD
Moclobemide—Migraine—Varenicline—nicotine dependence	0.015	0.0207	CcSEcCtD
Moclobemide—Irritability—Varenicline—nicotine dependence	0.0146	0.0201	CcSEcCtD
Moclobemide—Dry skin—Varenicline—nicotine dependence	0.014	0.0193	CcSEcCtD
Moclobemide—Gastritis—Varenicline—nicotine dependence	0.0135	0.0186	CcSEcCtD
Moclobemide—Abdominal distension—Varenicline—nicotine dependence	0.0133	0.0183	CcSEcCtD
Moclobemide—Angina pectoris—Varenicline—nicotine dependence	0.0128	0.0177	CcSEcCtD
Moclobemide—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.0121	0.0482	CbGpPWpGaD
Moclobemide—MAOB—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.0119	0.0472	CbGpPWpGaD
Moclobemide—Stomatitis—Varenicline—nicotine dependence	0.0115	0.0158	CcSEcCtD
Moclobemide—Conjunctivitis—Varenicline—nicotine dependence	0.0114	0.0158	CcSEcCtD
Moclobemide—Bradycardia—Varenicline—nicotine dependence	0.0107	0.0148	CcSEcCtD
Moclobemide—Hallucination—Varenicline—nicotine dependence	0.0105	0.0145	CcSEcCtD
Moclobemide—CYP2C19—Xenobiotics—CYP2A7—nicotine dependence	0.0105	0.0416	CbGpPWpGaD
Moclobemide—Visual impairment—Varenicline—nicotine dependence	0.0102	0.014	CcSEcCtD
Moclobemide—Tinnitus—Varenicline—nicotine dependence	0.00983	0.0136	CcSEcCtD
Moclobemide—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00964	0.0383	CbGpPWpGaD
Moclobemide—CYP2C9—Xenobiotics—CYP2A7—nicotine dependence	0.00956	0.038	CbGpPWpGaD
Moclobemide—Flatulence—Varenicline—nicotine dependence	0.00905	0.0125	CcSEcCtD
Moclobemide—Dysgeusia—Varenicline—nicotine dependence	0.00899	0.0124	CcSEcCtD
Moclobemide—Vision blurred—Varenicline—nicotine dependence	0.00865	0.0119	CcSEcCtD
Moclobemide—Tremor—Varenicline—nicotine dependence	0.0086	0.0119	CcSEcCtD
Moclobemide—Ill-defined disorder—Varenicline—nicotine dependence	0.00852	0.0118	CcSEcCtD
Moclobemide—Agitation—Varenicline—nicotine dependence	0.00844	0.0116	CcSEcCtD
Moclobemide—Malaise—Varenicline—nicotine dependence	0.00828	0.0114	CcSEcCtD
Moclobemide—Syncope—Varenicline—nicotine dependence	0.00823	0.0114	CcSEcCtD
Moclobemide—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00817	0.0325	CbGpPWpGaD
Moclobemide—Palpitations—Varenicline—nicotine dependence	0.00811	0.0112	CcSEcCtD
Moclobemide—Loss of consciousness—Varenicline—nicotine dependence	0.00807	0.0111	CcSEcCtD
Moclobemide—Hypertension—Varenicline—nicotine dependence	0.00793	0.0109	CcSEcCtD
Moclobemide—Myalgia—Varenicline—nicotine dependence	0.00782	0.0108	CcSEcCtD
Moclobemide—Chest pain—Varenicline—nicotine dependence	0.00782	0.0108	CcSEcCtD
Moclobemide—Anxiety—Varenicline—nicotine dependence	0.00779	0.0108	CcSEcCtD
Moclobemide—Discomfort—Varenicline—nicotine dependence	0.00772	0.0107	CcSEcCtD
Moclobemide—Haloperidol—DRD2—nicotine dependence	0.00768	0.321	CrCbGaD
Moclobemide—Dry mouth—Varenicline—nicotine dependence	0.00765	0.0106	CcSEcCtD
Moclobemide—MAOA—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00745	0.0296	CbGpPWpGaD
Moclobemide—Shock—Varenicline—nicotine dependence	0.00737	0.0102	CcSEcCtD
Moclobemide—Tachycardia—Varenicline—nicotine dependence	0.00731	0.0101	CcSEcCtD
Moclobemide—Hyperhidrosis—Varenicline—nicotine dependence	0.00724	0.01	CcSEcCtD
Moclobemide—Hypotension—Varenicline—nicotine dependence	0.007	0.00967	CcSEcCtD
Moclobemide—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00683	0.00942	CcSEcCtD
Moclobemide—Insomnia—Varenicline—nicotine dependence	0.00678	0.00936	CcSEcCtD
Moclobemide—Dyspnoea—Varenicline—nicotine dependence	0.00668	0.00922	CcSEcCtD
Moclobemide—Somnolence—Varenicline—nicotine dependence	0.00666	0.0092	CcSEcCtD
Moclobemide—Dyspepsia—Varenicline—nicotine dependence	0.0066	0.00911	CcSEcCtD
Moclobemide—Decreased appetite—Varenicline—nicotine dependence	0.00651	0.00899	CcSEcCtD
Moclobemide—Fatigue—Varenicline—nicotine dependence	0.00646	0.00892	CcSEcCtD
Moclobemide—Constipation—Varenicline—nicotine dependence	0.00641	0.00885	CcSEcCtD
Moclobemide—MAOB—Biological oxidations—CYP2A7—nicotine dependence	0.00631	0.0251	CbGpPWpGaD
Moclobemide—Feeling abnormal—Varenicline—nicotine dependence	0.00618	0.00852	CcSEcCtD
Moclobemide—Gastrointestinal pain—Varenicline—nicotine dependence	0.00613	0.00846	CcSEcCtD
Moclobemide—Urticaria—Varenicline—nicotine dependence	0.00595	0.00822	CcSEcCtD
Moclobemide—Abdominal pain—Varenicline—nicotine dependence	0.00592	0.00818	CcSEcCtD
Moclobemide—Asthenia—Varenicline—nicotine dependence	0.00538	0.00742	CcSEcCtD
Moclobemide—Pruritus—Varenicline—nicotine dependence	0.0053	0.00732	CcSEcCtD
Moclobemide—Diarrhoea—Varenicline—nicotine dependence	0.00513	0.00708	CcSEcCtD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00512	0.0203	CbGpPWpGaD
Moclobemide—Dizziness—Varenicline—nicotine dependence	0.00496	0.00684	CcSEcCtD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00485	0.0193	CbGpPWpGaD
Moclobemide—Vomiting—Varenicline—nicotine dependence	0.00476	0.00658	CcSEcCtD
Moclobemide—Rash—Varenicline—nicotine dependence	0.00473	0.00652	CcSEcCtD
Moclobemide—Dermatitis—Varenicline—nicotine dependence	0.00472	0.00652	CcSEcCtD
Moclobemide—Headache—Varenicline—nicotine dependence	0.00469	0.00648	CcSEcCtD
Moclobemide—Nausea—Varenicline—nicotine dependence	0.00445	0.00614	CcSEcCtD
Moclobemide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00435	0.0173	CbGpPWpGaD
Moclobemide—CYP2C19—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00429	0.0171	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.0041	0.0163	CbGpPWpGaD
Moclobemide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.004	0.0159	CbGpPWpGaD
Moclobemide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00397	0.0158	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—CYP2A7—nicotine dependence	0.00396	0.0157	CbGpPWpGaD
Moclobemide—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00395	0.0157	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHRNB3—nicotine dependence	0.00392	0.0156	CbGpPWpGaD
Moclobemide—CYP2C9—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00392	0.0156	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHRNA6—nicotine dependence	0.00372	0.0148	CbGpPWpGaD
Moclobemide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00353	0.014	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00351	0.0139	CbGpPWpGaD
Moclobemide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00339	0.0135	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00336	0.0134	CbGpPWpGaD
Moclobemide—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00335	0.0133	CbGpPWpGaD
Moclobemide—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00324	0.0129	CbGpPWpGaD
Moclobemide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00322	0.0128	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00313	0.0124	CbGpPWpGaD
Moclobemide—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00275	0.0109	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00274	0.0109	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—GABRA4—nicotine dependence	0.00269	0.0107	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHRNB4—nicotine dependence	0.00258	0.0102	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00255	0.0101	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00249	0.00988	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHRNA5—nicotine dependence	0.0024	0.00952	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00224	0.00892	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.00204	0.0081	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00199	0.0079	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHRNA3—nicotine dependence	0.00195	0.00776	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—CYP2A7—nicotine dependence	0.00187	0.00745	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00185	0.00734	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00183	0.00727	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00181	0.0072	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00172	0.00685	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHRNB2—nicotine dependence	0.00172	0.00683	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—CYP2A7—nicotine dependence	0.00171	0.00679	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.0017	0.00676	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00169	0.0067	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHRNA4—nicotine dependence	0.00156	0.00621	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00155	0.00616	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.00146	0.0058	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00144	0.00572	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CYP2A7—nicotine dependence	0.00108	0.00429	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CYP2A7—nicotine dependence	0.000677	0.00269	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CYP2A7—nicotine dependence	0.00032	0.00127	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000295	0.00117	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CYP2A7—nicotine dependence	0.000292	0.00116	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.00025	0.000992	CbGpPWpGaD
